Dr. Reddy’s Warns Over Currency Effects As Emerging Markets Slide
This article was originally published in PharmAsia News
Executive Summary
Indian generic drug giant Dr. Reddy’s says the crash of currencies in some emerging markets may impact earnings as it reported a tough third-quarter in which net profit was sharply below market expectations.
You may also be interested in...
Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.
Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.